Rapid growth for Pacira Pharmaceuticals' (PCRX -1.54%) time-release surgical painkiller Exparel is lifting profit as sales are leveraged against fixed costs, but a bigger opportunity may be ahead if the company can execute on plans to boost Exparel's addressable market. If so, the rapid run-up in Pacira Pharmaceuticals shares in October may be the start, rather than the end, for this company.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
